CLINICAL_TRIALS
trial_result
· 2025-01-07
Clinical Trial Update: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata [Phase 2]
Summary
A Phase 2 study evaluating DAXDILIMAB for moderate-to-severe Alopecia Areata has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Alopecia Areata | Phase 2 | Status: COMPLETED | Results posted: 2025-01-07